FDA Alerts

Following two trials, the FDA has approved the first treatment for molluscum contagiosum.

Following three clinical trials, the FDA has approved a new preventive treatment for neonates, infants, and toddlers that prevents respiratory syncytial virus (RSV) in those age populations.

The FDA has approved the first daily oral contraceptive for the prevention of pregnancy that does not require a health care provider’s prescription.

Following two studies, the FDA has approved the first cellular therapy for the treatment of type 1 diabetes in patients.

The FDA approved the first treatment for pediatric patients who experience functional constipation

This FDA Roundup includes an at-a-glance look at the latest FDA drug approvals in April and May, including treatment for menopausal hot flashes, Clostridioides difficile infection, suspected opioid...

The US FDA recently approved a novel treatment for moderate to severe vasomotor symptoms that are caused by menopause.

The FDA has approved the first orally administered treatment for the gut infection—clostridioides difficile.

The FDA’s approval of nalmefene hydrochloride nasal spray marks the first of its kind for health care and community use.

After clinical trials to assess the safety, efficacy, and maintenance use, the FDA has approved the first oral treatment for moderately to severely active Crohn disease.